EnGeneIC Announces First Patient Dosed in Recurrent Glioblastoma Clinical Trial

EnGeneIC Limited today announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGeneIC Dream Vector) therapy in patients with recurrent glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer.

You can view the publication here. 

Learn more about EnGeneIC Dream Vector (EDV™) Nanocell platform technology